291 related articles for article (PubMed ID: 36894873)
21. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
[TBL] [Abstract][Full Text] [Related]
22. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
[TBL] [Abstract][Full Text] [Related]
23. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
[TBL] [Abstract][Full Text] [Related]
24. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
25. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
26. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
27. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
29. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
30. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
[TBL] [Abstract][Full Text] [Related]
31. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
32. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
33. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
34. Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report.
Kohatsu K; Suzuki T; Takimoto M; Matsui K; Hashiguchi A; Koike J; Shirai S
BMC Nephrol; 2022 Nov; 23(1):367. PubMed ID: 36384506
[TBL] [Abstract][Full Text] [Related]
35. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
36. Renal effects of immune checkpoint inhibitors.
Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
[TBL] [Abstract][Full Text] [Related]
37. AKI in Patients Receiving Immune Checkpoint Inhibitors.
Perazella MA; Sprangers B
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
[No Abstract] [Full Text] [Related]
38. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
39. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A
Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899
[TBL] [Abstract][Full Text] [Related]
40. Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study.
Haeuser L; Marchese M; Cone EB; Noldus J; Bayliss G; Kilbridge KL; Trinh QD
Nephrol Dial Transplant; 2022 Jun; 37(7):1310-1316. PubMed ID: 34028534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]